Premium Nahrungsergänzungsmittel | artgerecht

Fecal Transplantation – Definition and Application

Fecal transplantation transfers stool from a healthy donor into a patient´s gut to restore the intestinal microbiome and treat conditions such as recurrent C. difficile infections.

Regular tips about health Regular tips about health

Things worth knowing about "Fecal Transplantation"

Fecal transplantation transfers stool from a healthy donor into a patient´s gut to restore the intestinal microbiome and treat conditions such as recurrent C. difficile infections.

What is Fecal Transplantation?

Fecal transplantation – also known as fecal microbiota transplantation (FMT) or stool transplantation – is a medical procedure in which processed stool from a healthy donor is transferred into the gastrointestinal tract of a patient. The goal is to restore the disrupted gut microbiome (the community of microorganisms living in the intestine) of the recipient and re-establish a healthy microbial balance.

The gut microbiome plays a key role in digestion, immune function, and overall health. When this balance is disturbed by illness or antibiotic use, fecal transplantation can help restore it effectively.

Indications and Uses

The most well-established and evidence-supported use of fecal transplantation is the treatment of recurrent Clostridioides difficile infections (formerly known as Clostridium difficile) that do not respond adequately to antibiotics. In addition, FMT is being investigated in clinical trials for the following conditions:

Inflammatory bowel diseases (e.g., ulcerative colitis, Crohn's disease)
Irritable bowel syndrome (IBS)
Metabolic syndrome and obesity
Neurological conditions related to the gut-brain axis
Gut colonization with multidrug-resistant organisms

How the Procedure Works

Donor Screening and Stool Preparation

Before transplantation, the donor undergoes thorough screening including comprehensive blood and stool tests to rule out infectious diseases and pathogenic organisms. The donated stool is then diluted with a sterile saline solution and filtered to create a homogeneous suspension. Freeze-dried capsules are also used in some protocols.

Routes of Administration

The prepared donor suspension can be administered in several ways:

Colonoscopy: direct delivery into the large intestine
Enema: a simpler, less invasive method
Nasogastric or nasoduodenal tube: delivery through the nose into the stomach or small intestine
Oral capsules: freeze-dried stool preparations taken by swallowing

Effectiveness and Success Rates

For recurrent Clostridioides difficile infections, fecal transplantation demonstrates success rates of over 85–90%, making it significantly more effective than repeated antibiotic therapy. For other conditions such as ulcerative colitis, clinical studies report remission rates of approximately 24–32%, with ongoing research continuing to evaluate its potential.

Risks and Side Effects

Fecal transplantation is generally considered safe when performed by experienced medical professionals. Possible risks and side effects include:

Temporary discomfort such as bloating, abdominal cramps, or diarrhea following the procedure
Transmission of pathogens if donor screening is inadequate
In rare cases, serious infections (e.g., transmission of multidrug-resistant organisms – documented in individual case reports)
Risks associated with the route of administration itself (e.g., complications during colonoscopy)

Regulatory Status and Availability

In the United States, the FDA has approved FMT-based products for the prevention of recurrent Clostridioides difficile infections. In Europe, regulatory classification varies by country, with FMT categorized either as a medicinal product or a tissue transplant depending on national law. The procedure is performed in specialized centers and is broadly recognized for C. difficile treatment, while use for other indications remains largely within clinical trials.

References

Surawicz CM et al. – Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infections. American Journal of Gastroenterology, 2013; 108(4):478–498.
Paramsothy S et al. – Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. The Lancet, 2017; 389(10075):1218–1228.
U.S. Food and Drug Administration (FDA): Fecal Microbiota Transplantation – Information for Health Care Providers, 2023. Available at: www.fda.gov

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.